Immunotech Laboratories Osake

Immunotech Laboratories PEG

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Immunotech Laboratories (IMMB) 26.8.2026 päivämäärällä.

PEG

0,00

Viimeksi päivitetty:

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Immunotech Laboratories on 2026 0,00 . PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä Immunotech Laboratories oli 2025 - . Se laskee % matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

Immunotech Laboratories Osakeanalyysi

Mitä Immunotech Laboratories tekee? Immunotech Laboratories Inc is a biotechnology company specializing in the development and marketing of immunotherapies for the treatment of various diseases. The company was founded in 2005 in California, USA. Immunotech Laboratories focuses on the development of immunotherapies for diseases such as HIV/AIDS, Hepatitis C, cancer, and autoimmune diseases. The business model of Immunotech Laboratories is based on the development of innovative immunotherapies using natural compounds. The company collaborates closely with leading scientists and experts in the field of immunology. The developed therapies undergo various clinical trials and are commercially distributed upon successful approval. Immunotech Laboratories specializes in different areas in order to offer a wide range of therapies to its customers. For example, the company develops immunotherapies for the treatment of HIV/AIDS. Immunotech Laboratories combines different compounds to reduce viral load in the body and aid the immune system in fighting the infection. Another important area for Immunotech Laboratories is the development of immunotherapies for cancer treatment. The company utilizes innovative approaches that enable the body's natural defenses to recognize and combat cancer cells. Combination of different compounds is also employed to enhance effectiveness. In addition to these areas, Immunotech Laboratories also offers immunotherapies for the treatment of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. The company employs innovative approaches that enable the immune system to recognize and fight pathogens causing these diseases. Immunotech Laboratories offers a range of products developed based on immunotherapies. These include different combinations of compounds for the treatment of HIV/AIDS and Hepatitis C, as well as immunotherapies for cancer and autoimmune diseases. These products are available in the form of injections, capsules, or tablets and can be prescribed by physicians. Overall, Immunotech Laboratories is an innovative biotechnology company specializing in the development and marketing of immunotherapies. The company collaborates with leading experts in immunology and develops innovative approaches for the treatment of various diseases. The offered products are known for their high effectiveness and tolerability, helping patients worldwide improve their health. Immunotech Laboratories on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset Immunotech Laboratories osakkeesta

Eurpoolissa voit löytää PEG-suhde (Hinta-tuotto-kasvu-suhde) Immunotech Laboratories:n täydellisen historiallisen kehityksen vuodesta 2006 lähtien – vuotuisten arvojen, kaavioiden ja yksityiskohtaisen analyysin kanssa.

PEG-suhde korjaa P/E-suhteen odotetulla tuottojen kasvuvauhdilla. PEG alle 1 voi viitata osakkeeseen, joka on aliarvostettu suhteessa sen kasvupotentiaaliin.

PEG = P/E-suhde / Odotettu vuosittainen EPS-kasvuprosentti

Arvioidakseen PEG-suhde (Hinta-tuotto-kasvu-suhde):n, on olennaista verrata sitä saman alan ja sektorin kilpailijoihin. Eulerpoolissa voit löytää suoria alan vertailuja PEG-suhde (Hinta-tuotto-kasvu-suhde):lle.

"Hyvä" vaihtelee alan ja yrityksen kehitysvaiheen mukaan. Eulerpoolissa voit verrata PEG-suhde (Hinta-tuotto-kasvu-suhde):n Immunotech Laboratories alan vertaisiin ja alan keskiarvoon arvioidaksesi houkuttelevuuden.

Access this data via the Eulerpool API

Arvostus — Immunotech Laboratories

Kaikki tunnusluvut — Immunotech Laboratories